BR112014006683A2 - nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; e nanoestrutura - Google Patents

nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; e nanoestrutura

Info

Publication number
BR112014006683A2
BR112014006683A2 BR112014006683A BR112014006683A BR112014006683A2 BR 112014006683 A2 BR112014006683 A2 BR 112014006683A2 BR 112014006683 A BR112014006683 A BR 112014006683A BR 112014006683 A BR112014006683 A BR 112014006683A BR 112014006683 A2 BR112014006683 A2 BR 112014006683A2
Authority
BR
Brazil
Prior art keywords
nanostructure
group
manganese
nanostructures
nanoparticle
Prior art date
Application number
BR112014006683A
Other languages
English (en)
Other versions
BR112014006683B1 (pt
Inventor
Ek Fredrik
Axelsson Oskar
Lauritzson Petter
M Petoral Rodrigo Jr
Original Assignee
Spago Imaging Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spago Imaging Ab filed Critical Spago Imaging Ab
Publication of BR112014006683A2 publication Critical patent/BR112014006683A2/pt
Publication of BR112014006683B1 publication Critical patent/BR112014006683B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C08G73/0213—Preparatory process
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Silicon Polymers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; e nanoestrutura são reveladas na presente invenção nanoestruturas que compreendem uma armação polimérica que compreende pelo menos cinco grupos de bisfosfonato geminado, em que os grupos de bisfosfonato geminado independentemente um do outro são incorporados como -r3r4c(p=o(or1)(or2))2, em que r1 e r2 são independentemente selecionados do grupo que consiste em uma carga negativa, h, alquila e arila, e em que pelo menos um dentre r3 e r4 é um grupo conectado à armação polimérica com a condição de que quando apenas um dentre r3 e r4 é tal grupo conectado, o outro dentre r3 e r4 é um grupo com capacidade conexão com a armação polimérica ou o resíduo de tal grupo ou selecionado do grupo que consiste em h, oh, or5 e r5, em que r5 é um alquila inferior. a armação polimérica pode compreender íons de manganês. são também revelados métodos para produzir tais nanoestruturas que contêm manganês, composições que compreendem tais nanoestruturas que contêm manganês e uso de tais nanoestruturas que contêm manganês, isto é, como agentes de contraste de mri.
BR112014006683-3A 2011-09-23 2012-09-20 nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; método para obter nanoestrutura; e nanoestrutura BR112014006683B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11182528.7 2011-09-23
EP11182528A EP2572736A1 (en) 2011-09-23 2011-09-23 Nanostructures comprising manganese
PCT/EP2012/068541 WO2013041623A1 (en) 2011-09-23 2012-09-20 Novel manganese comprising nanostructures

Publications (2)

Publication Number Publication Date
BR112014006683A2 true BR112014006683A2 (pt) 2017-03-28
BR112014006683B1 BR112014006683B1 (pt) 2021-02-09

Family

ID=46852040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006683-3A BR112014006683B1 (pt) 2011-09-23 2012-09-20 nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; método para obter nanoestrutura; e nanoestrutura

Country Status (15)

Country Link
US (1) US9040637B2 (pt)
EP (2) EP2572736A1 (pt)
JP (1) JP6103605B2 (pt)
KR (1) KR101965017B1 (pt)
CN (1) CN103930136B (pt)
AU (1) AU2012311522B2 (pt)
BR (1) BR112014006683B1 (pt)
CA (1) CA2847804C (pt)
DK (1) DK2750716T3 (pt)
ES (1) ES2774777T3 (pt)
IL (1) IL231563A (pt)
PL (1) PL2750716T3 (pt)
RU (1) RU2638535C2 (pt)
WO (1) WO2013041623A1 (pt)
ZA (1) ZA201402759B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593027B2 (en) * 2012-03-02 2017-03-14 The Regents Of The University Of California Porous metal oxide and metal oxide-organic nanocomposites, methods of making and uses thereof
EP2923712A1 (en) 2014-03-28 2015-09-30 Spago Imaging AB Nanostructures and applications thereof
AU2015249222A1 (en) * 2014-04-25 2016-11-17 Naurex, Inc. Stable compositions of neuroactive peptides
EP3180036B1 (en) * 2015-04-24 2018-11-28 Duke University Metal complexes with bisphosphonate useful as imaging agents
CN105037743B (zh) * 2015-07-14 2017-06-16 河南科技大学 一种二乙二醇木质素溶剂以及木质素分离提取方法
EP3183009B1 (en) 2015-09-30 2023-08-09 Duke University Contrast agents for magnetic resonance imaging
EP3348560A1 (en) 2017-01-16 2018-07-18 Spago Nanomedical AB Chemical compounds for coating of nanostructures
RU2709215C1 (ru) * 2019-09-12 2019-12-17 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук" (ИК СО РАН) Способ подавления роста опухолей глиального происхождения
EP4242250A1 (en) 2022-03-08 2023-09-13 Spago Nanomedical AB Compounds for coating of nanostructures
EP4241792A1 (en) 2022-03-08 2023-09-13 Spago Nanomedical AB Nanostructures and applications thereof
EP4241765A1 (en) 2022-03-08 2023-09-13 Spago Nanomedical AB Globular nanostructures having an anchoring layer
EP4241793A1 (en) * 2022-03-08 2023-09-13 Spago Nanomedical AB Globular nanostructures

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440738A (en) * 1982-06-10 1984-04-03 Mallinckrodt, Inc. Stable radiographic imaging agents
JPS58222095A (ja) * 1982-06-16 1983-12-23 Lion Corp キレート剤
JPS61151104A (ja) * 1984-12-25 1986-07-09 Tokuyama Soda Co Ltd 歯科用接着性被膜形成材
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
US5200554A (en) * 1992-01-21 1993-04-06 Nasman Jan Anders H Bisphosphonic acid derivatives and their use
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
US6541454B1 (en) * 1995-04-04 2003-04-01 Yissum Research Development Company Of The Hebrew University Jerusalem Phosphonates, biphosphonates and pharmaceutical compositions containing them
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
EP1390081A2 (en) * 2001-01-08 2004-02-25 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
FR2848850B1 (fr) * 2002-12-20 2005-06-24 Guerbet Sa Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
US20040206932A1 (en) * 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
US7449111B2 (en) * 2003-07-30 2008-11-11 Arkema Inc. Resins containing ionic or ionizable groups with small domain sizes and improved conductivity
FR2862651B1 (fr) * 2003-11-24 2006-03-31 Rhodia Cons Spec Ltd Nouveaux dendrimeres a terminaisons bisphosphoniques et derives, leur procede de preparation et leur utilisation
NZ587774A (en) * 2004-05-24 2012-03-30 Warner Chilcott Co Llc Enteric solid oral dosage form of bisphosphonate containing a chelating agent
US7396880B2 (en) * 2005-05-24 2008-07-08 Arkema Inc. Blend of ionic (co)polymer resins and matrix (co)polymers
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
FR2913886B1 (fr) * 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
WO2008148174A1 (en) * 2007-06-08 2008-12-11 Queensland University Of Technology Wound repair composition and method
US20090047318A1 (en) * 2007-08-16 2009-02-19 Abbott Cardiovascular Systems Inc. Nanoparticle-coated medical devices and formulations for treating vascular disease
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
ES2366758T3 (es) * 2008-10-22 2011-10-25 Clariant Finance (Bvi) Limited Compuestos de fosfonato olefínicamente insaturados, polímeros fabricados a partir de ellos, y su uso.
WO2010135167A1 (en) 2009-05-18 2010-11-25 Arkema Inc. Copolyelectrolyte monomers bearing multiple acid groups
FR2946973B1 (fr) * 2009-06-23 2011-08-12 Univ Claude Bernard Lyon Nouveau procede de preparation de nanoparticules a base de fluorure de terre rare
EP2329951B1 (en) * 2009-12-04 2012-06-20 AGFA Graphics NV A lithographic printing plate precursor
US9315524B2 (en) * 2012-05-07 2016-04-19 Kumar Ranjan Bhushan Magnetic resonance imaging agents for calcification

Also Published As

Publication number Publication date
IL231563A0 (en) 2014-04-30
PL2750716T3 (pl) 2020-06-29
CA2847804A1 (en) 2013-03-28
DK2750716T3 (da) 2020-03-30
WO2013041623A1 (en) 2013-03-28
CA2847804C (en) 2020-07-07
CN103930136B (zh) 2015-10-21
JP6103605B2 (ja) 2017-03-29
EP2750716B1 (en) 2019-12-25
BR112014006683B1 (pt) 2021-02-09
AU2012311522A1 (en) 2014-03-20
JP2014534277A (ja) 2014-12-18
IL231563A (en) 2016-09-29
ZA201402759B (en) 2015-07-29
EP2750716A1 (en) 2014-07-09
RU2638535C2 (ru) 2017-12-14
CN103930136A (zh) 2014-07-16
KR101965017B1 (ko) 2019-04-02
ES2774777T3 (es) 2020-07-22
KR20140064990A (ko) 2014-05-28
US9040637B2 (en) 2015-05-26
EP2572736A1 (en) 2013-03-27
RU2014111802A (ru) 2015-10-27
AU2012311522B2 (en) 2016-12-22
US20140350193A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
BR112014006683A2 (pt) nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; e nanoestrutura
TW201613855A (en) Sulfonic acid derivatives and photoacid generator
ES2540463T3 (es) Electrolito híbrido
GB201203582D0 (en) Sulfonamide-containing photoresist compositions and methods of use
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
AR102389A1 (es) Profármacos de carbidopa y l-dopa y métodos de uso de los mismos, kit
MX355921B (es) Composicion para el cuidado bucal antimanchas.
AT516600A5 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX362199B (es) Compuestos y composiciones de poliglicerilo cationicos.
BR112014014148A2 (pt) misturas de ácidos difosfínicos e dialquilfosfínicos, processo para produção das mesmas e uso das mesmas
GT201300084A (es) Conjugado de naloxol-peg cristalino
TR201904639T4 (tr) Muskarinik M1 reseptörü pozitif allosterik modülatörler.
PH12016501343A1 (en) Emulsion composition for skin
BR112013008876A2 (pt) "motor tendo propriedades aprimoradas"
WO2013045382A3 (en) Hair composition
JP2015048478A5 (pt)
BR112014022516A8 (pt) Rotor para motor ou gerador
PH12015501489A1 (en) Compositions
IN2014DN03197A (pt)
ES2617070T3 (es) Composición de fosfonato de fluoroalquilo
BR112015001989A8 (pt) uso de butilidenoftalida (bp)
UY28828A1 (es) Nueva forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s, 6s-2,8-diazabiciclo(4.3.0)nonan-8-il)-6-fluoro-1,4-dihidro-4-oxo-3-quinolincarboxílico
BR112015026295A2 (pt) processo para regenerar composto iônico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: SPAGO NANOMEDICAL AB (SE)

B25G Requested change of headquarter approved

Owner name: SPAGO NANOMEDICAL AB (SE)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2012, OBSERVADAS AS CONDICOES LEGAIS.